2a4r: Difference between revisions
No edit summary |
No edit summary |
||
Line 4: | Line 4: | ||
|PDB= 2a4r |SIZE=350|CAPTION= <scene name='initialview01'>2a4r</scene>, resolution 2.40Å | |PDB= 2a4r |SIZE=350|CAPTION= <scene name='initialview01'>2a4r</scene>, resolution 2.40Å | ||
|SITE= | |SITE= | ||
|LIGAND= | |LIGAND= <scene name='pdbligand=BNH:[(N-{3-[(N-{CYCLOHEXYL[(ISOBUTOXYCARBONYL)AMINO]ACETYL}-3-CYCLOPROPYLALANYL)AMINO]-4-CYCLOPROPYL-2-OXOBUTANOYL}GLYCYL)AMINO](PHENYL)ACETIC+ACID'>BNH</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene> | ||
|ACTIVITY= | |ACTIVITY= | ||
|GENE= | |GENE= | ||
|DOMAIN= | |||
|RELATEDENTRY=[[1a1r|1A1R]], [[2a4g|2A4G]], [[1jxp|1JXP]], [[1n1l|1N1L]], [[1ns3|1NS3]], [[1rtl|1RTL]] | |||
|RESOURCES=<span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2a4r FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2a4r OCA], [http://www.ebi.ac.uk/pdbsum/2a4r PDBsum], [http://www.rcsb.org/pdb/explore.do?structureId=2a4r RCSB]</span> | |||
}} | }} | ||
Line 32: | Line 35: | ||
[[Category: Prongay, A.]] | [[Category: Prongay, A.]] | ||
[[Category: Saksena, A K.]] | [[Category: Saksena, A K.]] | ||
[[Category: virus/viral protein]] | [[Category: virus/viral protein]] | ||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Mar 31 01:47:51 2008'' |
Revision as of 01:47, 31 March 2008
| |||||||
, resolution 2.40Å | |||||||
---|---|---|---|---|---|---|---|
Ligands: | , | ||||||
Related: | 1A1R, 2A4G, 1JXP, 1N1L, 1NS3, 1RTL
| ||||||
Resources: | FirstGlance, OCA, PDBsum, RCSB | ||||||
Coordinates: | save as pdb, mmCIF, xml |
HCV NS3 Protease Domain with a Ketoamide Inhibitor Covalently bound.
OverviewOverview
Modification of the P(2) and P(1) side chains of earlier P(3)-capped alpha-ketoamide inhibitor of HCV NS3 serine protease 1 resulted in the discovery of compound 24 with about 10-fold improvement in potency.
About this StructureAbout this Structure
2A4R is a Protein complex structure of sequences from Hepatitis c virus. Full crystallographic information is available from OCA.
ReferenceReference
Hepatitis C virus NS3-4A serine protease inhibitors: use of a P2-P1 cyclopropyl alanine combination for improved potency., Bogen S, Saksena AK, Arasappan A, Gu H, Njoroge FG, Girijavallabhan V, Pichardo J, Butkiewicz N, Prongay A, Madison V, Bioorg Med Chem Lett. 2005 Oct 15;15(20):4515-9. PMID:16112862
Page seeded by OCA on Mon Mar 31 01:47:51 2008